vida: extract claims from 2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance

- Source: inbox/queue/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md
- Domain: health
- Claims: 2, Entities: 2
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-04-28-llm-vs-human-glp1-coaching-commoditization-limit
 scope: structural
 sourcer: Nicholas Thompson via CNBC 2026
 supports: ["glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt", "ai-native-health-companies-achieve-3-5x-the-revenue-productivity-of-traditional-health-services-because-ai-eliminates-the-linear-scaling-constraint-between-headcount-and-output"]
-related: ["fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm", "glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt", "healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary"]
+related: ["fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm", "glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt", "healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
 ---
 
 # AI-driven GLP-1 telehealth prescribing achieves billion-dollar scale with minimal staffing but generates systematic safety and fraud failures
 
 A 2-person AI-staffed GLP-1 telehealth startup reached $1.8 billion in sales run-rate in 2026, using AI to replace all traditional operational roles: engineering teams, marketers, support staff, and analysts. This represents complete commoditization of the drug access layer—pure prescribing without behavioral support infrastructure. However, this low-end commoditization generated systematic failures: FDA warnings and multiple active lawsuits over AI-generated patient photos and deepfaked before-and-after images. The company operates at the prescribing-only layer, not the clinical behavioral support layer where companies like Omada, Noom, and Calibrate compete. This bifurcation demonstrates that AI can fully automate drug access but cannot replicate clinical oversight, behavioral coaching infrastructure, or physical data integration (CGM monitoring, nutritional support, adherence tracking). The $1.8B scale with 2 employees proves the drug access layer is economically commoditized, but the legal and regulatory failures prove it is clinically inadequate. This supports the thesis that value in GLP-1 care is shifting to the behavioral + physical integration layer that AI telehealth cannot replicate.
+
+
+## Supporting Evidence
+
+**Source:** National Geographic 2025
+
+BMI 16 anorexia patient acquired GLP-1 online by lying about weight. Most patients receive NO eating disorder evaluation before prescription. Psychologist Robyn Pashby: clinicians must 'hold two truths' — efficacy for some, harm risk for others — but screening infrastructure absent.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: NEDA and ANAD recommend physician + ED therapist + dietitian before prescribing GLP-1s to at-risk patients, but this care team structure does not exist in primary care where 70+ percent of GLP-1 prescriptions are written
+confidence: experimental
+source: NEDA/ANAD clinical guidance 2025
+created: 2026-05-04
+title: GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate
+agent: vida
+sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md
+scope: structural
+sourcer: NEDA/ANAD
+supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support"]
+---
+
+# GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate
+
+NEDA and ANAD jointly recommend that GLP-1 prescribing for patients with eating disorder risk factors require a tri-specialist care team: a physician versed in both GLP-1s and eating disorders, a therapist experienced with both GLP-1s and ED treatment, and a dietitian familiar with this medication class and recovery nutrition. This guidance is professional society recommendation only—it creates no regulatory requirement and no legal obligation. The structural problem: most GLP-1 prescriptions originate in primary care settings where none of these three specialists are available. Primary care physicians typically lack eating disorder training, do not have ED therapists on staff, and rarely coordinate with dietitians for medication management. The gap is not that PCPs don't know the guidance exists—it's that the recommended care infrastructure does not exist in the settings where prescribing actually happens. This is compounded by the fact that eating disorder specialists are even more supply-constrained than general mental health providers. The guidance documents best practice while being structurally unimplementable at the point of care.

domains/health/glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Nausea and vomiting experienced by 40 percent of GLP-1 users overlap precisely with bulimia nervosa purging behaviors, creating a mechanism where the drug's most common adverse effects can worsen eating disorder symptoms
+confidence: experimental
+source: ANAD clinical guidance 2025
+created: 2026-05-04
+title: GLP-1 GI side effects trigger purging behaviors in vulnerable populations creating direct pharmacological harm pathway not just psychological reinforcement
+agent: vida
+sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md
+scope: causal
+sourcer: ANAD
+related: ["glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+---
+
+# GLP-1 GI side effects trigger purging behaviors in vulnerable populations creating direct pharmacological harm pathway not just psychological reinforcement
+
+ANAD documents that GLP-1 receptor agonists' most common side effects—nausea, vomiting, diarrhea, and gastroparesis—'can trigger or worsen purging behaviors' in individuals with eating disorder histories or vulnerabilities. This is not an indirect psychological effect but a direct pharmacological pathway to harm. Approximately 40 percent of GLP-1 users experience significant GI side effects. For patients with bulimia nervosa or purging-type eating disorders, these medication-induced symptoms overlap precisely with their disorder's behavioral patterns. The drug creates the physical sensation (nausea) that the disorder interprets as a cue for purging behavior. This is distinct from the appetite suppression mechanism—it's about the adverse effect profile creating a trigger for maladaptive coping. The guidance notes this requires 'hydration and electrolyte monitoring' because the combination of medication-induced vomiting and eating disorder purging creates compounding medical risk. This mechanism was not widely discussed in the GLP-1 literature prior to eating disorder specialists documenting it.

entities/health/anad.md

@@ -0,0 +1,35 @@
+---
+title: National Association of Anorexia Nervosa and Associated Disorders (ANAD)
+type: entity
+entity_type: organization
+domain: health
+status: active
+---
+
+# National Association of Anorexia Nervosa and Associated Disorders (ANAD)
+
+Oldest U.S. eating disorder advocacy organization, founded 1976. Provides clinical guidance, support groups, and treatment resources.
+
+## Timeline
+
+- **2025-01-01** — Published joint clinical guidance with NEDA on GLP-1 receptor agonist use in eating disorder populations, documenting that GI side effects 'can trigger or worsen purging behaviors' and recommending tri-specialist care teams with hydration/electrolyte monitoring
+
+## Overview
+
+ANAD focuses on eating disorder treatment access, clinical standards, and patient advocacy. Their guidance documents clinical best practices but carries no regulatory authority.
+
+## Key Clinical Positions
+
+**GLP-1 Monitoring Requirements (2025):**
+- Hydration and electrolyte levels (vomiting + GI side effects pose serious risk)
+- Emergence of restrictive eating behaviors
+- Weight loss rate and magnitude
+- Eating disorder symptom changes via standardized measures
+
+**Required Care Team:**
+- Physician versed in GLP-1s and eating disorders
+- Therapist experienced with both GLP-1s and ED treatment
+- Dietitian familiar with this medication class and recovery nutrition
+
+**Documented Risks:**
+ANAD notes that GI side effects (nausea, vomiting, diarrhea, gastroparesis) 'can trigger or worsen purging behaviors' in vulnerable individuals, creating a direct pharmacological harm pathway. Approximately 2/3 of weight loss returns within one year if medication stops, creating weight cycling risk particularly harmful for ED populations.

entities/health/neda.md

@@ -0,0 +1,30 @@
+---
+title: National Eating Disorders Association (NEDA)
+type: entity
+entity_type: organization
+domain: health
+status: active
+---
+
+# National Eating Disorders Association (NEDA)
+
+Leading U.S. advocacy and clinical guidance organization for eating disorder treatment and prevention.
+
+## Timeline
+
+- **2025-01-01** — Published joint clinical guidance with ANAD on GLP-1 receptor agonist use in eating disorder populations, recommending tri-specialist care teams and identifying contraindications including current/past anorexia nervosa, active restrictive behaviors, and severe body image issues
+
+## Overview
+
+NEDA provides clinical guidance, advocacy, and resources for eating disorder treatment. Their recommendations carry professional authority but no regulatory force—guidance creates clinical standards without legal mandates.
+
+## Key Positions
+
+**GLP-1 Contraindications (2025):**
+- Current or past anorexia nervosa or atypical anorexia nervosa
+- Active restrictive behaviors, bingeing, or purging
+- Severe body image issues or unstable recovery
+- Lack of appropriate monitoring or multidisciplinary support
+- Signs the medication is being sought solely for weight loss
+
+NEDA notes there are no FDA warnings for eating disorder populations—all guidance is professional society recommendation only.

inbox/archive/health/2025-xx-national-geographic-glp1-eating-disorder-clinical-concerns.md

@@ -7,10 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-04
 priority: medium
 tags: [glp1, eating-disorders, clinical-concerns, prescribers, anorexia, atypical-anorexia, misuse, online-access]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md

@@ -7,10 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: clinical-guidance
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-04
 priority: medium
 tags: [glp1, eating-disorders, neda, anad, clinical-guidance, screening, contraindications, monitoring]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content